Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 157,174 | 200,445 | 201,587 | 233,912 | 193,701 |
| Receivables | 799,310 | 800,646 | 788,309 | 752,390 | 770,776 |
| Inventories | 292,972 | 285,280 | 262,584 | 255,809 | 261,522 |
| Other current assets | 93,314 | 113,389 | 91,713 | 107,580 | 97,087 |
| TOTAL | $1,444,325 | $1,504,780 | $1,448,355 | $1,439,032 | $1,415,352 |
| Non-Current Assets | |||||
| PPE Net | 1,525,485 | 1,529,640 | 1,494,080 | 1,465,655 | 1,380,568 |
| Investments And Advances | 301,847 | 300,281 | 293,787 | 311,602 | 0 |
| Intangibles | 3,770,888 | 3,846,483 | 3,859,746 | 3,805,178 | 2,834,126 |
| Other Non-Current Assets | 564,462 | 591,197 | 603,471 | 581,304 | 1,752,723 |
| TOTAL | $6,162,682 | $6,267,601 | $6,251,084 | $6,163,739 | $5,967,417 |
| Total Assets | $7,607,007 | $7,772,381 | $7,699,439 | $7,602,770 | $7,382,769 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 2,079 |
| Accounts payable and accrued liabilities | 136,341 | 140,204 | 120,004 | 205,915 | 181,629 |
| Accrued Expenses | 422,245 | 411,506 | 397,423 | 416,836 | 397,119 |
| Other current liabilities | 184,745 | 198,517 | 201,739 | 204,575 | 181,894 |
| TOTAL | $993,816 | $1,007,623 | $981,392 | $1,091,585 | $1,014,194 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,514,217 | 2,678,472 | 2,743,774 | 2,707,531 | 2,937,056 |
| Deferred Revenues | 250,485 | 257,396 | 262,226 | 264,259 | 251,473 |
| Other Non-Current Liabilities | 602,271 | 618,904 | 647,289 | 605,298 | 601,628 |
| TOTAL | $3,302,430 | $3,507,203 | $3,604,164 | $3,530,107 | $3,735,837 |
| Total Liabilities | $4,296,246 | $4,514,826 | $4,585,556 | $4,621,692 | $4,750,031 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 51,297 | 51,271 | 51,183 | 50,986 | 50,879 |
| Common Shares | 514 | 513 | 512 | 509 | 510 |
| Retained earnings | 1,720,441 | 1,633,052 | 1,536,032 | 1,432,901 | 1,279,567 |
| Other shareholders' equity | -263,314 | -202,395 | -233,850 | -257,272 | -390,215 |
| TOTAL | $3,310,761 | $3,257,555 | $3,113,883 | $2,981,078 | $2,632,738 |
| Total Liabilities And Equity | $7,607,007 | $7,772,381 | $7,699,439 | $7,602,770 | $7,382,769 |